Cell and Gene Therapy Development: Selecting the Right Contract Development and Manufacturing Organization In recent years, the number of cell and gene therapy (CGT) clinical trials has boomed, and so has the need for contract development and manufacturing organizations (CDMOs). For any size biotech company developing CGT products, selecting the right CDMO is crucial for […]
We are pleased to announce that Julie Osborne has joined SK pharmteco as VP, Global HR. Julie has held several progressing roles supporting Global Marketing and sales, Controlled Substance Manufacturing, Regulatory Affairs, Quality, and R&D. As a Division Vice President for Global Pharmaceutical R&D, Julie maintained Business and HR responsibilities across six countries, including Japan,
Julie Osborne joins SK pharmteco as VP, Global HR Read More »
At DCAT Week, the buzz wasn’t just about the latest drug discovery techniques – it was about AI’s growing influence on bio/pharma supply chains. SK pharmteco was at the forefront of this conversation when Jeet Sarkar, SK pharmteco’s global head of Information Technology (IT), took center stage on a panel discussing how biopharma companies utilize
AI in Bio/Pharma Supply Chain: SK pharmteco Expert Shares Insights at DCAT Week Read More »
The Korean CDMO’s new viral vector platforms can significantly save the production time and cost of AAV and lentiviral vectors By Ji-Hyun Lee SK pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), has recently introduced two new viral vector platforms that are expected to save the time and cost of
Designed to shorten turnaround on manufacturing AAVs, this new platform offers Cell and Gene Therapy developers more flexibility in producing viral vectors for clinical and commercial use Evry-Courcouronnes (near Paris), France, November 7, 2023 – Yposkesi, SK pharmteco’s European clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapies (C>), today launches AAVelocityTM,
RANCHO CORDOVA, Calif. and KING OF PRUSSIA, Pa., Oct. 18, 2023 /PRNewswire/ — SK pharmteco will participate at the CPHI 2023 in Barcelona and prepare a dedicated booth at the event. As a multi-modality CDMO with expertise in small molecule active pharmaceutical ingredients (APIs) and biopharmaceuticals, SK pharmteco aims to present its business competitiveness and actively pursue business opportunities. With a dedicated booth
SK pharmteco to Showcase its Extensive APIs and CGT Capabilities at CPHI 2023 Read More »
September 27, 2023 FOR IMMEDIATE RELEASE RANCHO CORDOVA, Ca. (September 27, 2023) – SK pharmteco, a global contract development and manufacturing organization serving the pharmaceutical industry, today announced Andrew (Andy) Fenny as Chief Commercial Officer. In this newly created role, Fenny will shape customer-focused strategies and be responsible for SK pharmteco’s sales and marketing initiatives and
SK pharmteco Names Andrew Fenny Chief Commercial Officer Read More »
On Sept. 15, 2023, CPHI Barcelona announced the finalists for the 2023 CPHI Pharma Awards. The awards ceremony will be held on Oct. 24, 2023, the opening day of CPHI Barcelona, the world’s largest pharma event, at the Fiera Barcelona. SK pharmteco (SKPT) was honored to be among 12 finalists in the “Accelerating Innovation” category.
SK pharmteco is a Pharma Award Finalist for CPHI Barcelona 2023 Read More »
September 19, 2023 FOR IMMEDIATE RELEASE – CBM brings extensive cell and gene therapy expertise to SK pharmteco portfolio and continues SK pharmteco’s strategy to deliver end-to-end, multi-modality support for clients – SK pharmteco previously invested $350 million in CBM in 2022 RANCHO CORDOVA, Ca. & KING OF PRUSSIA, Pa. (Sept. 20, 2023) – SK pharmteco
An open letter from our CEO, Joerg Ahlgrimm to SK pharmteco Customers SK pharmteco’s mission is to improve patient outcomes and save lives by partnering with our customers to produce and deliver life changing therapies through manufacturing and technical excellence, a positive and adaptable workforce, and an intense focus on safety, quality, and innovation. Our
An open letter from our CEO, Joerg Ahlgrimm, to SK pharmteco Customers Read More »
"*" indicates required fields
